Does Rallies show Form 4 insider transactions for LEXX?

Yes. Rallies tracks LEXX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LEXX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LEXX. It does not provide personalized investment advice.

LEXX (Lexaria Bioscience Corp. Common Stock) Stock Analysis - Insider Trades

Lexaria Bioscience Corp. Common Stock (LEXX) is a publicly traded Healthcare sector company. As of May 19, 2026, LEXX trades at $0.57 with a market cap of $14.68M and a P/E ratio of 0.00. LEXX moved -0.07% today. Year to date, LEXX is -14.36%; over the trailing twelve months it is -44.54%. Its 52-week range spans $0.46 to $3.39. Rallies surfaces LEXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LEXX stock inside the company?

Recent LEXX insider activity includes BUNKA CHRISTOPHER bought 11.90K, BUNKA CHRISTOPHER bought 15.60K, McKechnie William Edward bought 5.00K, DOCHERTY JOHN MARTIN bought 5.38K, and Carle Vanessa bought 750. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LEXX Key Metrics

Key financial metrics for LEXX
Metric	Value
Price	$0.57
Market Cap	$14.68M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$3.39
52-Week Low	$0.46
Volume	38.50K
Avg Volume	0
Revenue (TTM)	$705.92K
Net Income	$-11.91M
Gross Margin	99.61%

Recent LEXX Insider Trades

BUNKA CHRISTOPHER bought 11.90K (~$10.87K) on Jul 30, 2025.
BUNKA CHRISTOPHER bought 15.60K (~$14.38K) on Jul 29, 2025.
McKechnie William Edward bought 5.00K (~$4.53K) on Jul 29, 2025.
DOCHERTY JOHN MARTIN bought 5.38K (~$4.99K) on Jul 29, 2025.
Carle Vanessa bought 750 (~$682.5) on Jul 29, 2025.

Latest LEXX News

Lexaria Bioscience Secures IRB Approval for Five-Week DHT-Semaglutide Study Against Wegovy — May 19, 2026
Lexaria Extends Material Transfer Agreement Through 2026, Highlights GLP-1 Research — May 7, 2026
Lexaria Completes Manufacturing for Oral DHT-Semaglutide Study, Ethics Approval Submitted — May 5, 2026
Lexaria Launches 18-Arm GLP-1 Animal Study Testing Amycretin and Retatrutide — Apr 23, 2026
Lexaria Eyes Up to $60B Oral GLP-1 Pill Market with DehydraTECH — Apr 21, 2026

LEXX Analyst Consensus

LEXX analyst coverage data. Average price target: $0.00.

Common questions about LEXX

Who is trading LEXX stock inside the company?: Recent LEXX insider activity includes BUNKA CHRISTOPHER bought 11.90K, BUNKA CHRISTOPHER bought 15.60K, McKechnie William Edward bought 5.00K, DOCHERTY JOHN MARTIN bought 5.38K, and Carle Vanessa bought 750. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LEXX?: Yes. Rallies tracks LEXX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LEXX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LEXX. It does not provide personalized investment advice.